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Epidermal growth factor receptor (EGFR) is frequently amplified and/or mutated in a number of human tumours and abnormal
signalling from this receptor is believed to contribute to the malignant phenotype seen in these tumours. Gefitinib is a small molecule
inhibitor that specifically binds and inhibits the EGFR tyrosine kinase and has been shown to inhibit the growth, proliferation, survival
and invasion of a range of tumour cells overexpressing EGFR. However, clinical response to gefitinib has failed to correlate with EGFR
levels and activity, indicating that other molecular mechanisms such as downstream signalling and mutations could be of importance in
predicting clinical response. We therefore investigated the effect of the specific EGFR inhibitor gefitinib on the phosphorylation level,
signalling and growth of cells expressing the naturally occurring constitutively active EGFR variant EGFRvIII, a low nontransforming
level of EGFR and a high transforming level of EGFR. Results show that levels of gefitinib sufficient to suppress EGFR phosphorylations,
EGFR-mediated proliferation and EGFR-mediated anchorage-independent growth are not sufficient to inhibit these features in cells
expressing EGFRvIII. Furthermore, the data indicate that long-term exposure of EGFRvIII-expressing cells to low concentrations of
gefitinib (0.01–0.1mM) result in increased phosphotyrosine load of the receptor, increased signalling to ERK and stimulation of
proliferation and anchorage-independent growth, presumably by inducing EGFRvIII dimerisation. Higher concentrations of gefitinib
(1–2mM), on the other hand, significantly decreased EGFRvIII phosphotyrosine load, EGFRvIII-mediated proliferation and anchorage-
independent growth. Further studies are needed to investigate the implications of these important findings in the clinical setting.
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Receptor tyrosine kinases regulate signalling pathways involved in
critical cellular activities such as growth, proliferation, motility,
survival and apoptosis. When activated by overexpression,
autocrine growth factor stimulation or mutations, receptor
tyrosine kinases can contribute to the development of human
cancers. The epidermal growth factor receptor (EGFR, ErbB1) is a
tyrosine kinase receptor of the ErbB family and is frequently
overexpressed or mutated in human malignancies including those
of the brain, breast, colon, ovary and lung (Tang et al, 2000; Alper
et al, 2001; Ge et al, 2002; Peghini et al, 2002). This has inspired the
development of specific pharmacological inhibitors of the EGFR
tyrosine kinase such as gefitinib (Iressa, AstraZeneca Pharmaceu-
ticals), which disrupts EGFR kinase activity by reversibly binding
within the ATP-binding pocket of the EGFR protein (Arteaga and
Johnson, 2001). Gefitinib is orally active and has shown promising
antitumour activity in vitro and in vivo, although clinical response
has failed to correlate with either EGFR levels or activity. Recently,
however mutations were identified in the tyrosine kinase domain,
which were associated with sensitivity of non-small-cell lung
cancer to gefitinib (Lynch et al, 2004; Paez et al, 2004).
The type III epidermal growth factor mutation variously named,
EGFRvIII, DEGFR, de2-7EGFR and mEGFR is the most common
mutation in the EGFR gene and is frequently found in tumours of
the breast, ovary, prostate, lung and in particular those of the brain
(Garcia et al, 1993; Moscatello et al, 1995; Olapade-Olaopa et al,
2000; Pedersen et al, 2001; Ge et al, 2002). This mutation or
deletion eliminates exons 2–7 resulting in a truncated receptor
with a distorted ligand-binding area. However, despite lack of
ligand-binding EGFRvIII has a constitutively active receptor
tyrosine kinase and is able to transform fibroblasts and to confer
enhanced tumorigenicity to cancer cells both in vitro and in vivo
(Huang et al, 1997; Damstrup et al, 2002; Pedersen et al, 2004). A
recent study found that cells expressing EGFRvIII had increased
resistance to gefitinib in vitro and in vivo, which were attributed to
a deficiency in receptor dephosphorylation and constitutive AKT
activity (Learn et al, 2004). Hence, evidence accumulates that
signalling regulated by EGFR is altered by overexpression or
mutations and that such alterations can lead to differences in
response to gefitinib treatment.
The purpose of this study was to investigate the effect of
gefitinib on phosphorylation level, intracellular signalling and
growth properties of cells expressing EGFRvIII. However, there are
several complicating factors associated with the analysis of
EGFRvIII-mediated signalling in cancer cells. In particular, the
enhanced tumorigenicity conferred to cancer cells by EGFRvIII is
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spredominantly restricted to in vivo growth conditions making
detailed analyses problematic. Many cancer cells also express
significant levels of other members of the ErbB family that are
potentially capable of forming heterodimers with EGFRvIII
(O’Rourke et al, 1998).
Therefore we have used the unique NR6 model system, in which
NR6wtEGFR express a low nontransforming level of EGFR and the
fully tumorigenic cell lines NR6W and NR6M that overexpress
EGFR or express mutant EGFRvIII, respectively (Batra et al, 1995).
This allows us to characterise the effect of gefitinib on
phosphorylation and intracellular signalling by a nontransforming
level of EGFR, by a transforming level of EGFR and by a
transforming level of EGFRvIII.
Results show that some tyrosine phosphorylation sites on the
wild-type (wt)-EGFR are more resistant to inhibition by gefitinib
compared to others. Results also confirm that higher doses of
gefitinib are needed to abrogate phosphorylation of and signalling
to PLC-g and AKT by EGFRvIII as compared to wt-EGFR.
Furthermore, small levels of gefitinib seem to induce receptor
autophosphorylation, as well as proliferation and anchorage-
independent growth of EGFRvIII-expressing cells.
MATERIALS AND METHODS
Materials
Recombinant human EGF was purchased from Calbiochem
(Germany). Anti EGFR, phospho-EGFR (Tyr845, Tyr992,
Tyr1045, Tyr1068), STAT3, phospho-STAT3 (Tyr705), AKT,
phospho-AKT (Ser473), extracellular-regulated kinase (ERK)-1/2
and phospho-ERK-1/2 (Thr202/Tyr204) antibodies were from Cell
Signaling Technology (Germany). Antiphospho-EGFR (Tyr1148
and Tyr1173) antibodies were from Upstate Biotechnology (USA).
The antiphospho-EGFR (Tyr1086) antibody was from Biosource
(USA).
Antibody to tubulin was from Santa Cruz Biotechnology Inc.
(CA, USA). HRP-conjugated secondary antibodies were purchased
from, DAKO (Denmark).
Cell lines
Four cell lines were included in this work. The cell lines NR6,
NR6M and NR6W have been described previously and were kindly
provided by Dr Darell Bigner, Duke University, NC, USA (Batra
et al, 1995). The NR6wtEGFR cell line, which expresses a lower
number of receptors as compared to NR6W, has also been
described previously and is a generous gift from Dr Allan Wells,
Department of Pathology, University of Pittsburgh (Wells et al,
1990).
Immunoblot analyses
For determination of phosphorylated proteins, 5mg whole cell
lysate from serum-starved cells was resolved by SDS–PAGE and
electroblotted onto nitrocellulose membranes. After transfer and
blocking in 5% nonfat milk, primary antibody staining was carried
out by incubation overnight at 41C, and secondary antibody
staining was for 1h at room temperature. The chemiluminescence
detection method (ECL) was used for all Western blot experiments.
Crosslinking assay
Crosslinking of receptors were carried out as described (Mon-
tgomery, 2002). Briefly, gefitinib-treated cells were washed twice in
ice-cold phosphate-buffered saline (PBS) and solubilised in RIPA
buffer containing protease and phosphatase inhibitors, 10%
glycerol and 1mM bis(sulfosuccinimidyl) suberate (BS
3) for
20min at 41C. Glycine at a final concentration of 250mM was
subsequently added for 5min, followed by centrifugation at
14000g for 10min. Equivalent amounts of protein were resolved
by SDS–PAGE and electroblotted onto nitrocellulose membranes.
Blotting and antibody incubations were performed as above using
anti-EGFR and antiphospho-tyrosine antibodies.
Proliferation assay
Exponentially growing cells were seeded in sextuple in 96-well
plates at a concentration of 2000 cells/well, allowed to adhere and
subsequently washed in PBS and incubated overnight in medium
containing 0.5% FCS. Cells were then treated with varying
concentrations of Iressa or the solute control DMSO and EGF.
The optimal EGF concentration for inducing proliferation of
NR6wtEGFR and NR6W cells has previously been determined and
hence NR6wtEGFR and NR6W cells were added 10 and 0.1nM EGF,
respectively (Pedersen et al, unpublished observation). NR6 and
NR6M cells were not added EGF. After 72h the amount of cells
were measured by performing a 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) proliferation assay (Roche,
Denmark) (Hansen et al, 2003).
Soft agar assay for anchorage-independent growth
Exponentially growing cells (1 10
5) were suspended in 3ml 0.5%
(w/v) NuSieve low-melting agar (FMC, Rockland, ME, USA)
dissolved in DMEMþ0.5% FCS and plated in six-well plates
covered with 0.5% agar dissolved in DMEMþ0.5% FCS. Cells were
then treated with varying concentrations of Iressa or the solute
control DMSO. The optimal concentration of EGF for inducing
anchorage-independent growth of NR6wtEGFR and NR6W cells
has previously been determined and hence NR6wtEGFR were
added 10 and 0.1nM EGF, respectively (Pedersen et al, unpublished
observation). NR6 and NR6M were not stimulated with EGF.
Cultures in triplicate for each condition were replenished with
fresh medium once a week. After 3 weeks the plates were stained
with crystal violet and colonies 450 cells were counted.
RESULTS
Expression of ErbB family members in the cell lines
Epidermal growth factor receptor and EGFRvIII are known to form
heterodimers with other members of the ErbB receptor family,
which could potentially affect receptor phosphorylation and
downstream signalling. Thus, the levels of ErbB1 (EGFR), ErbB2
(HER-2), ErbB3 (HER-3) and ErbB4 (HER-4) in the four NR6 cell
lines: NR6, NR6wtEGFR, NR6W and NR6M were investigated by
immunoblotting (Figure 1). All four cell lines have comparable
levels of ErbB2, ErbB3 and ErbB4, which appear to be relatively low
as compared to the levels of EGFR and EGFRvIII. Consequently,
heterodimerisation most likely play a minor role in these cell lines.
Effect of gefitinib on inhibition of EGFR tyrosine
phosphorylations
To investigate the efficacy of gefitinib towards inhibition of wt and
mutant EGF receptors, we evaluated the effect of varying
concentrations (0.001–2mM) of the inhibitor on receptor phos-
phorylations in the cell lines: NR6wtEGFR, NR6W and NR6M by
immunoblotting (Figure 2). Initially cells were serum starved
overnight to reduce baseline levels of phosphorylation. The cells
were then mock treated (DMSO only) or treated with increasing
concentrations of gefitinib for 5h, after which they were stimulated
with 10nM of EGF for 10min.
Immunoblot analysis of whole cell lysates revealed that in
general gefitinib effectively inhibited all tyrosine phosphorylation
sites on EGFR in both the high and low-EGFR-expressing cell lines
Gefitinib inhibition of EGFRvIII
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s(Figure 2A and B). However, the phosphorylation sites Tyr1173
and Tyr992 were less sensitive requiring higher concentrations of
gefitinib for inhibition. The calculated IC50 values for these sites
were 37nM (Tyr1173), 37nM (Tyr992), 26nM (Tyr1173) and 57nM
(Tyr992) in, respectively, the low and high EGFR expressing cell
lines (Table 1).
The tyrosine phosphorylation sites in the EGFRvIII-expressing
cell line, although sensitive to gefitinib, were all very durable
requiring 3–20 times higher doses for 50% inhibition as compared
to the wt-EGFR (Figure 2C and Table 1). The Tyr1173 and Tyr1148
were the sturdiest sites with IC50 values of 97 and 214nM,
respectively. Thus, although EGFRvIII has a lower level of
phosphorylation as compared to ligand-activated EGFR; the
phosphotyrosine residues are more resistant to inhibition by
gefitinib. Although an isolated increase in phosphorylation of
EGFRvIII on some tyrosine residues was noted in the NR6M cells
treated with 0.005 and 0.01mM (Figure 1C, lanes 4 and 5), this
result was not consistently seen on repeat experiments.
The average IC50 values for tyrosine phosphorylation of EGFR in
the low- and high-expressing cell lines were 22 and 21nM,
respectively, and thus independent of receptor expression levels.
In contrast the average IC50 value of EGFRvIII tyrosine phos-
phorylation was 84nM, suggesting that the EGFRvIII tyrosine
kinase is approximately four times as resistant to gefitinib as EGFR
(Table 1).
Differential inhibition of intracellular signalling by
gefitinib
The effect of gefitinib on the status of the major downstream
targets of EGFR and EGFRvIII were also investigated. Extracellular
regulated kinase-1 and -2 (ERK-2), phospholipase C g (PLC-g),
protein kinase B (AKT) and the signal transducer and activator of
transcription 3 (STAT3) are all essential downstream targets of
EGFR and mediate many of its oncogenic effects.
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Figure 1 Expression of the ErbB family members in the cell lines
described in these experiments as measured by immunoblotting using
specific antibodies.
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Figure 2 Profiles of EGF- (10nM for 10min) induced phosphorylation of various tyrosine residues of EGFR in the presence of varying concentrations of
gefitinib in (A) the low-EGFR-expressing cell line NR6wtEGFR and (B) the high-EGFR-expressing cell line NR6W. (C) Profiles of constitutive
phosphorylation of various tyrosine residues of EGFRvIII in the presence of varying concentrations of gefitinib. The phosphorylations were determined by
immunoblotting of whole cell lysates with antibodies that specifically recognise the phosphorylated amino-acid residues Tyr845, Tyr992, Tyr1045, Tyr1068,
Tyr1086, Tyr1148 and Tyr1173. Total EGFR or EGFRvIII levels are also indicated. (D) Bands were quantified using Kodak Digital Science Software version
1.0 corrected for total receptor level and plotted as a percentage of the phosphorylation levels in the untreated cells (lower panel). Exposures of the various
blots are optimised for quantitative detection of IC50 and thus not directly comparable.
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expressing cell line, but not significantly in the high-EGFR-
expressing cell line (Figure 3A). The EGFRvIII-expressing cell line
had a low level of constitutively phosphorylated ERK as a result of
the constitutively active receptor (Figure 3A). Using a concentra-
tion gradient it was found that higher concentrations of gefitinib
were needed to inhibit ERK signalling (IC50 of 394 and 356nM,
respectively) as compared to the receptor phosphorylations (IC50
of 22 and 84nM, respectively) in the NR6wtEGFR and NR6M cell
lines (Table 2, Figure 3B and D). ERK phosphorylations in the
NR6W cell line in contrast were unresponsive to gefitinib even at
the highest concentrations indicating that the ERK activity in this
cell line is not mediated by the EGFR (Figure 3C).
As opposed to the level of ERK phosphorylation the high
EGFR-expressing cell line had a substantial level of PLC-g phos-
phorylation after EGF stimulation as compared to the low-EGFR-
and -EGFRvIII-expressing cell lines, respectively (Figure 3A). Gefitinib
effectively blocked this phosphorylation with a calculated IC50 of
27nM (Table 2 and Figure 3C). The NR6wtEGFR and NR6M cell
lines had low levels of PLC-g phosphorylations but the level in the
NR6M cell line was more resistant to inhibition by gefitinib (IC50
of 43 and 369nM, respectively) see Table 2, Figure 3B and D.
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Figure 3 (A) Phosphorylation of key signalling molecules upon EGF (10nM for 10min) stimulation in the four cell lines. Profiles of EGF- (10nM for 10min)
induced phosphorylation of various downstream signalling molecules of EGFR in cells pretreated with varying concentrations of gefitinib in (B) the low-
EGFR-expressing cell line NR6wtEGFR and (C) in the high-EGFR-expressing cell line NR6W. (D) Profiles of EGFRvIII-induced phosphorylation of various
downstream signalling molecules of EGFR in the presence of varying concentrations of gefitinib in the EGFRvIII-expressing cell line NR6M. The
phosphorylations and total levels of the signalling molecules were determined by immunoblotting of whole cell lysates with antibodies that specifically
recognise the total and phosphorylated species of ERK, PLC-g, AKT and STAT3.
Table 1 IC50 (nM) of specific EGFR tyrosine phosphorylation site inhibition by gefitinib
EGFR tyrosine phosphorylation sites
Cells Tyr1173 Tyr1148 Tyr1086 Tyr1068 Tyr1045 Tyr992 Tyr845 Average
NR6wtEGFR 37 17 20 2 13 37 6 22
NR6W 26 5 12 3 4 57 18 21
NR6M 97 214 47 45 — 47 52 84
Table 2 IC50 (nM) of specific signalling molecule phosphorylation site
inhibition by gefitinib
Inhibition of phosphorylation sites
Cells PLC-c AKT ERK STAT3 Average
NR6wtEGFR 43 220 394 17 169
NR6W 27 7 — 8 11
NR6M 369 263 356 — 329
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low-EGFR- and -EGFRvIII-expressing cell lines and unresponsive
to EGF in the high-EGFR- and -EGFRvIII-expressing cell lines
(Figure 3A). As was the case for ERK, gefitinib fails to effectively
inhibit AKT phosphorylation in the high-EGFR-expressing cell line
indicating that EGFR is not the major activator of AKT in this cell
line. The low IC50 (7nM), however show that the weak induction of
AKT phosphorylation by EGFR in this cell line is efficiently
blocked by gefitinib (Table 2). Gefitinib inhibits AKT phos-
phorylations, with IC50 values of 220 and 263nM,i nt h el o w - E G F R -a n d
–EGFRvIII-expressing cell lines, respectively (Table 2, Figure 3B, C
and D). Only the wt receptor is able to activate STAT3 upon EGF
stimulation of both the high- and low-EGFR-expressing cell lines
(Figure 3A). Of the downstream targets of EGFR, STAT3 seems to
be most dependent on high receptor phosphorylation. STAT3
phosphorylation is completely abolished at IC50 values of 17 and
8n M, which is comparable to the levels needed for inhibition of
receptor autophosphorylation (Table 2, Figure 3B and C). There is
no effect of gefitinib on the very low background level of STAT3
phosphorylation in the EGFRvIII-expressing cell line.
Inhibition of EGFRvIII driven cell proliferation requires
higher concentrations of gefitinib than wt EGFR
The rate of proliferation in the absence of gefitinib was higher in
the EGFR- and EGFRvIII-expressing cell lines, as compared to the
parental cell line NR6 (Figure 4A). Gefitinib had no effect on NR6
proliferation in the concentration range investigated. In contrast,
proliferation of cells expressing EGFR decreased significantly,
reaching a level similar to the parental cell line at a gefitinib
concentration of 1mM. Proliferation of cell expressing EGFRvIII was
more resistant to inhibition by gefitinib requiring a concentration
of 2mM to reach a level comparable to that of the parental cell line
(Figure 4A) The calculated IC50 values for inhibition of EGFR- and
EGFRvIII-mediated proliferation were 0.97 and 0.52mM for the low-
and high-EGFR-expressing cell lines, respectively, and 7.58mM for
the EGFRvIII-expressing cell line (Figure 4B).
Notably, low levels of gefitinib (0.05–0.25mM) resulted in a
slight, but statistically significant (Po0.05), increase in prolifera-
tion of EGFRvIII-expressing cells as compared to mock-treated
cells (Figure 4A).
Low concentrations of gefitinib increases the number of
colonies of EGFRvIII-expressing cells
To investigate the effect of gefitinib on EGFRvIII-mediated
transformation colony formation assays were performed in
semisolid agar. Results confirmed that in the absence of gefitinib
NR6W and NR6M cells readily form colonies in soft agar, whereas
NR6wtEGFR cells require 10nM EGF for weak colony formation
(Figure 5). A gefitinib concentration above 0.1mM decreases the
colony-forming ability of NR6W and NR6wtEGFR cells and a
concentration of 1.5mM completely abolishes the ability of these
cell lines to form colonies.
Surprisingly, gefitinib in the dose range from 0.1 to 0.5mM
significantly facilitates, rather than abrogate, colony formation of
NR6M cells. However, at a concentration of 2mM gefitinib
completely blocks NR6M colony formation, as seen for the
EGFR-expressing cell lines.
Gefitinib-induced dimerisation of wt and mutant EGFR
As can be seen in Figure 6C gefitinib induces the formation of
EGFR and EGFRvIII homodimers at concentrations of 0.01mM and
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Figure 4 Effect of gefitinib on cell proliferation. (A) Graphical
presentation of raw absorbance measurements for NR6, NR6wtEGFR,
NR6W and NR6M cells treated with 0–2mM gefitinib for 72h. NR6,
NR6wtEGFR and NR6W cells were stimulated with EGF. This figure is
representative of 15 independent experiments; bars, 7s.e. *Po0.05
(compared to control treatment), **Po0.01 (compared to control
treatment). (B) Proliferation plotted as a percentage of the viability in
the untreated cells; bars, 7s.e.
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Figure 5 Growth of NR6 cells in soft agar in the presence and absence
of gefitinib. (A) Graphical presentation of raw colony counts (left y-axis)
and number of colonies plotted as a percentage of colonies in the
untreated cells (right y-axis) for NR6, NR6wtEGFR, NR6W and NR6M cells
treated with 0–2mM gefitinib and grown in soft agar for 18 days.
NR6wtEGFR and NR6W were stimulated with 10 and 0.1nM, respectively.
This figure is representative of three independent experiments; bars, 7s.e.
#Po0.05 (increase as compared to control treatment), *Po0.05 (decrease
as compared to control treatment).
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sabove in the NR6W and NR6M cell lines. Furthermore, anti-
phosphotyrosine and antiphospho EGFR (Tyr1173) immunoblot
analyses (Figure 6A and B) indicate that gefitinib in the
concentration range 0.01–0.1mM increases the level of tyrosine-
phosphorylated EGFRvIII monomers and homodimers. A higher
gefitinib concentration (1mM) decreases the phosphotyrosine load
of both monomers and dimers to levels lower than the untreated
controls. In contrast, although gefitinib induces EGFR homo-
dimerisation in the high-EGFR-expressing cell line, a strong
decrease in phosphotyrosine load is found for both the monomer
and dimer bands (Figure 6). This indicates that the induction of
activated dimers by gefitinib only takes place in cells expressing
EGFRvIII. Of note, the band with a molecular weight approxi-
mating EGFRvIII detected in the NR6W and NR6wtEGFR cell lines
is not EGFRvIII as confirmed using RT–PCR and antibodies
specific for EGFRvIII (data not shown). Rather, it possibly
represents a degraded form of EGFR, the level of which depends
on the lysis buffer, the primary antibody and the homogenisation
procedure.
Durability of gefitinib inhibition in vitro
A recent study has suggested that short-term treatment with
gefitinib does not reduce phosphorylation of EGFRvIII and that
repeated administration of gefitinib is necessary (Learn et al,
2004). Thus, to estimate the durability of gefitinib inhibition in
vitro, an experiment was performed investigating the levels of
EGFR/EGFRvIII and ERK phosphorylation in cells mock treated or
treated with 0.1 or 2mM of gefitinib and at the same time
stimulated with 10nM EGF for 10min, 24, 48 and 72h (Figure 7).
The tyrosine phosphorylation site 1173 was selected, as it was the
most durable of the phosphorylation sites. The results show that
gefitinib rapidly and in a dose-dependent manner inhibits EGFR
and ERK phosphorylations up to 72h after EGF stimulation in
both the high- and low-EGFR-expressing cell lines (Figure 7A and
B). The decrease in EGFR levels, in the absence of gefitinib, in the
low-EGFR-expressing cell line is due to receptor downregulation
induced by EGF, a mechanism that appears not to be functioning
in the NR6W and NR6M cell lines.
A concentration of 0.1mM gefitinib seems to increase EGFRvIII
phosphorylation on residue 1173 and ERK phosphorylation after
48 and 72h of treatment (Figure 7C). This could explain why
gefitinib in low concentrations induce cell proliferation- and
anchorage-independent growth. In contrast 2mM of gefitinib
effectively inhibits both EGFRvIII and ERK phosphorylations in
the NR6M cell line for up to 72h. It is noteworthy that the high
concentration of gefitinib seems to induce degradation of both
EGFR and EGFRvIII independent of EGF. This is particularly
evident in the low-EGFR-expressing cell line where 0.1mM gefitinib
inhibit EGF-mediated downregulation, presumably due to its
inhibition of the Tyr1045 site, but fails to do so at a concentration
of 2mM (Figure 7A).
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Figure 6 Dimerisation induction by gefitinib. Monolayer NR6wtEGFR, NR6W and NR6M cells were exposed to gefitinib for 24h followed by exposure
to the chemical crosslinker (BS
3) followed by immunoblot analysis using (A) anti-EGFR(pTyr1173), (B) antiphospho-tyrosine (PY-20) and (C) anti-EGFR
and antibodies.
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Phosphorylation of EGFR tyrosine residue 1173, AKT and
ERK are least susceptible to inhibition by gefitinib
Gefitinib effectively inhibits phosphorylation of seven major
tyrosine phosphorylation sites on EGFR and does so in cells
expressing both low and high levels of EGFR. However, the
effectiveness of inhibition of the individual sites varies with the
Tyr1173 and Tyr992 being the more resistant in both cell lines. The
levels of gefitinib sufficient to suppress EGFR phosphorylation are
not sufficient to inhibit EGFRvIII phosphorylation. Average
tyrosine phosphorylation of EGFRvIII being roughly four times
more resistant to inhibition by gefitinib compared to the wt
receptor with Tyr1148 and Tyr1173 being the more resistant sites.
Thus, Tyr1173 appears to be the sturdiest tyrosine phosphoryla-
tion site in both EGFR and EGFRvIII requiring the highest
concentration of gefitinib for inhibition. Tyr1173 is a major
binding site for the adapter protein SHC and mediates activation of
the RAS/RAF/MEK/ERK pathway (Batzer et al, 1994; Okabayashi
et al, 1994). This is in concurrence with the observed persistence of
ERK phosphorylation in the three cell lines even at high gefitinib
concentrations.
As for ERK, the phosphorylation of AKT was resistant to
gefitinib inhibition. The phosphorylation site(s) that mediates
AKT phosphorylation is ill-defined, although Tyr1068 and Tyr1086
have been implicated through their binding to GRB2-associated
binding protein 1 (GAB-1) (Rodrigues et al, 2000). As both
Tyr1068 and Tyr1086 were sensitive to gefitinib inhibition it seems
as if weakly phosphorylated receptors are able to facilitate AKT
phosphorylation. The gefitinib-sensitive SRC (v-src sarcoma viral
oncogene homolog) phosphorylation site Tyr845 on EGFR has
been shown to mediate activation of STAT3, and indeed loss of
EGF-dependent phosphorylation of STAT3 in response to gefitinib
appears to be tightly coupled to suppression of EGFR auto-
phosphorylation (Sato et al, 2003; Shao et al, 2003). Although
EGFRvIII was phosphorylated on Tyr845, it was unable to induce
STAT3 phosphorylation.
In general, the levels of gefitinib sufficient to inhibit the tyrosine
phosphorylation sites on EGFR and EGFRvIII were insufficient to
inhibit the downstream-signalling pathways, although phosphor-
ylation of STAT3 was an exception. We believe that this is due to
the amplification of the receptor signal seen by most signalling
cascades (Mayawala et al, 2004). Targeting one or more kinases
downstream of EGFR and EGFRvIII such as MEK, ERK or AKT
could thus potentially increase the effectiveness of gefitinib. STAT3
is an exception as it binds directly to the receptor and following
phosphorylation the protein translocates to the nucleus.
Epidermal growth factor receptorvIII-mediated cell
proliferation and anchorage-independent growth is both
resistant and stimulated by gefitinib
Like EGFRvIII phosphorylation and signalling, EGFRvIII-driven
proliferation and anchorage-independent growth was found to be
less sensitive to inhibition by gefitinib compared to EGFR.
However, the level of gefitinib required for inhibition of these
cellular properties was much higher than those needed for
inhibition of receptor phosphorylation. The relative instability of
inhibitor over extended periods at room temperature may explain
the discrepancy between gefitinib levels that were needed for 50%
inhibition of proliferation (IC50 of 7.58mM) and colony formation
(IC50 of 2mM) and those that were needed for 50% inhibition of
autophosphorylation (average IC50 of 0.091mM).
Surprisingly, however, our results suggest not only that
EGFRvIII-driven proliferation of NR6M cells is resistant to
inhibition by gefitinib, but also appear to be enhanced by
treatment with the inhibitor in the concentration range 0.05–
0.25mM. A similar effect was observed for EGFRvIII-mediated
anchorage-independent growth of NR6M cells, where colony
formation was both resistant to and even stimulated by gefitinib
in concentrations between 0.1 and 0.5mM.
Although a novel finding with regard to gefitinib, similar
inductions of proliferation and colony formation of both EGFR-
and EGFRvIII-expressing cells have been described in the literature
with other quinazoline tyrosine kinase inhibitors (Montgomery,
2002; Li et al, 2003). Montgomery found that the EGFR-specific
quinazoline inhibitor AG1478 at a concentration of 0.1mM
stimulated colony formation of EGFRvIII-expressing cells (Mon-
tgomery, 2002). Similarly Li et al (2003) reported that PD153035
stimulated the proliferation of LN229/EGFR cells at 0.05mM. Thus,
this seems to be a general effect of EGFR-specific quinazoline
inhibitors, when used at certain concentrations.
The mechanism by which quinazolines increase proliferation
and anchorage-independent growth of EGFRvIII-expressing cells is
uncertain. We did not see an effect on phosphotyrosine load of and
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Figure 7 Duration of EGFR and EGFRvIII and ERK inhibition by gefitinib in the NR6wtEGFR, NR6W and NR6M cell lines. Profiles of EGFR and ERK
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and 3). However, upon prolonged exposure (424h) of EGFRvIII-
expressing cells to gefitinib in the concentration range 0.01–0.1mM,
EGFRvIII formed dimers and the phosphotyrosine load increased
in both monomers and dimers. This is consistent with findings by
Montgomery, who showed that AG1478 induced dimers of
EGFRvIII in the concentration range 0.001-0.01mM, and that dimers
similarly had increased phosphotyrosine load (Montgomery, 2002).
Addition of higher concentrations of both gefitinib and AG1478
maintain the level of EGFRvIII dimers, but the phosphotyrosine
load decreases accordingly. We speculate that EGFR-specific
quinazoline inhibitors in certain concentrations, depending on its
stability and the level of receptor, capture EGFRvIII in its dimer
form. As the gefitinib concentration gradually decreases over time,
it reaches a level where the receptor captured in the complexes is
able to transphosphorylate the dimer partner. This is further
supported by the observation that gefitinib in a concentration of
0.1mM initially (10min–24h) inhibited EGFRvIII phosphorylations
on Tyr1173 and ERK, but after 48h increased their phosphoryla-
tions (Figure 7). Higher concentrations (2mM) effectively blocked
EGFRvIII and ERK phosphorylations for up to 72h.
Although gefitinib was proficient at inducing dimers of EGFR in
the high-EGFR-expressing cell line no increase in phosphotyrosine
load could be detected. On the contrary gefitinib effectively
inhibited phosphotyrosine load of both dimers and monomers.
Are the concentrations of gefitinib that stimulate EGFRvIII
dimerisation, induce NR6M proliferation and anchorage-indepen-
dent growth relevant in a clinical setting?
A recent study showed that daily oral dosing in the 400–
600mgday
 1 range result in mean plasma concentrations ranging
from 478 to 620ngml
 1 (1.07–1.39mM) (Baselga et al, 2002).
Assuming that the intratumour concentration equals the mean
plasma concentration EGFRvIII phosphorylation and signalling
should to be blocked, although cells are still proliferating at a
higher rate than the control cells. However, if a lower daily dosing
schema (225mgday
 1) is selected, the mean plasma concentration
decreases to 160ngml
 1 (0.36mM) (Baselga et al, 2002). At this
concentration EGFRvIII is able to induce phosphorylation of both
ERK- and AKT- and EGFRvIII-mediated cell proliferation is largely
unaffected. However, it is possible that by maintaining a daily high
dosing scheme, the unwanted stimulation of EGFRvIII by gefitinib
may be avoided, and this warrants further investigations in the
clinical setting.
In summary this study shows that gefitinib blocks EGFR- and
EGFRvIII-mediated phosphorylation and signalling, although
higher concentrations are needed for effective inhibition of
EGFRvIII. A similar resistance to gefitinib was observed on
EGFRvIII-driven proliferation and anchorage-independent growth.
In addition, our data provide evidence that long-term exposure of
EGFRvIII-expressing cells to low concentrations of gefitinib
augment EGFRvIII phosphorylation, signalling, cellular prolifera-
tion and anchorage-independent growth. Further studies are
needed to investigate the implications of these findings in a more
clinical setting.
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